Oncolytics Biotech Inc (ONCY) – aksjekurser og nyheter

Symboler Symboler	Pris	Endring	Endring (%)	Trend	Forrige pris ved stengetid	Åpne	Høy	Lav	Volum	Markedsverdi
SIXB Materials SIXB Materials	SIXB −0,21%	1 091,51	−2,30	−0,21%	—	1 093,81	1 096,52	1 100,22	1 091,51	—	—
SIXC Communications SIXC Communications	SIXC +0,22%	610,11	+1,34	+0,22%	—	608,77	608,77	612,97	608,77	—	—
SIXE Energy SIXE Energy	SIXE −1,34%	1 237,98	−16,83	−1,34%	—	1 254,81	1 253,01	1 253,87	1 226,33	—	—
SIXI Industrials SIXI Industrials	SIXI −0,93%	1 744,71	−16,40	−0,93%	—	1 761,11	1 764,27	1 766,88	1 744,71	—	—
SIXM Financials SIXM Financials	SIXM −0,37%	640,18	−2,40	−0,37%	—	642,58	644,87	648,48	640,18	—	—
SIXR Staples SIXR Staples	SIXR −0,18%	849,58	−1,55	−0,18%	—	851,13	855,66	858,75	845,56	—	—
SIXRE Real estate SIXRE Real estate	SIXRE −0,23%	217,48	−0,50	−0,23%	—	217,98	217,98	218,65	216,88	—	—
SIXT Technology SIXT Technology	SIXT +1,52%	3 260,69	+48,86	+1,52%	—	3 211,83	3 227,21	3 268,38	3 226,55	—	—
SIXU Utilities SIXU Utilities	SIXU −0,69%	942,45	−6,53	−0,69%	—	948,98	948,58	957,83	941,97	—	—
SIXV Health care SIXV Health care	SIXV −0,52%	1 466,80	−7,72	−0,52%	—	1 474,52	1 479,03	1 481,04	1 466,80	—	—
SIXY Discretionary SIXY Discretionary	SIXY +0,22%	2 397,50	+5,38	+0,22%	—	2 392,12	2 396,95	2 421,22	2 382,32	—	—

ONCY:NASDAQ

Oncolytics Biotech Inc

0,87 USD

−1,12%

(−0,0099) 1 D

0,89 USD

+2,06% (+0,018)

Etter stengetid

Stengt: 1. mai, 16:00:00 GMT-4 · USD

Alle symboler

1 D

5 D

1 M

6 M

I år

1 Å

5 Å

MAKS

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for ONCY …

Åpne

0,90 USD

Høy

0,92 USD

Lav

0,87 USD

Markedsverdi

101,04 mill.

Snittvolum

872,50k

Volum

677,92k

52 u høy

1,51 USD

52 u lav

0,33 USD

EPS

−0,30 USD

Utestående aksjer

116,13 mill.

Antall ansatte

Relaterte aksjer

AUPH

Aurinia Pharmaceuticals Inc

Iovance Biotherapeutics Inc

3,40 USD

+1,19%

VTGN

Vistagen Therapeutics Inc

0,63 USD

+2,02%

Nyhetssaker

Fra kilder på nettet

Simply Wall Street

for 1 minutt siden

Preformed Line Products Robotics Move Raises Questions Around Rich Valuation

Seeking Alpha

for 28 minutter siden

Wall Street strategists stay calm as stocks rip higher, but BofA sees reasons for caution

MSN

for 33 minutter siden

S&P 500 profits haven’t been this rich in at least 15 years — but there’s more to the story

Yahoo Finance

for 3 timer siden

5 things we learned during S&P 500 earnings madness

Profil

Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia

Om Oncolytics Biotech Inc

Administrerende direktør-

Ansatte29

Grunnlagt1998

HovedkontorCalgary, Alberta, Canada

Sektor-

Nettstedoncolyticsbiotech.com

Alle verdier i CAD	des. 2024	mars 2025	juni 2025	sep. 2025
Inntekt	-	-	-	-
Varekostnad	-	-	-	-
Direkte driftskostnader	-	-	-	-
Utgifter til forskning og utvikling	-	4,08 mill.	2,81 mill.	7,52 mill.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	-	2,92 mill.	2,90 mill.	6,32 mill.
Driftskostnader	-	7,00 mill.	5,71 mill.	13,84 mill.
Totale driftskostnader	-	7,00 mill.	5,71 mill.	13,84 mill.
Driftsinntekter	-	−7,00 mill.	−5,71 mill.	−13,84 mill.
Andre ikke-operasjonelle inntekter	-	240,00k	−196,00k	−1,05 mill.
EBT inkludert uvanlige elementer	-	−6,69 mill.	−6,08 mill.	−14,65 mill.
EBT uten uvanlige elementer	-	−6,69 mill.	−6,08 mill.	−14,65 mill.
Kostnad for inntektsskatt	-	-	85,00k	−252,00k
Faktisk avgiftssats	-	-	−1,40 %	1,72 %
Andre driftskostnader	-	-	-	-
Nettoinntekt	-	−6,69 mill.	−6,16 mill.	−14,40 mill.
Netto fortjenestemargin	-	-	-	-
Resultat per aksje	−0,10	−0,08	−0,07	−0,14
Rente- og investeringsinntekter	-	123,00k	104,00k	100,00k
Rentekostnader	-	-	-	-
Netto rentekostnader	-	123,00k	104,00k	100,00k
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	-	−6,97 mill.	−5,68 mill.	−13,82 mill.
Gevinst eller tap ved salg av eiendeler	-	-	-	-

AI-innhold kan inneholde feil. Finn ut mer

HjelpSend tilbakemeldingPersonvern Vilkår Ansvarsfraskrivelse

Finance

Utforskning